0001522767 false --12-31 2021 Q2 337000 962,571 907,285 10/17/2018 10/16/2020 11/7/2018 11/6/2020 5/8/2019 5/7/2021 6/28/2019 6/27/2021 8/20/2019 8/19/2021 2/21/2020 2/20/2021 P3Y 1032000 P4Y P3Y P5Y P5Y P3Y four years P3Y 1 5 5 0001522767 2021-01-01 2021-06-30 0001522767 2021-08-16 0001522767 2021-06-30 0001522767 2020-12-31 0001522767 MRMD:SeriesBConvertiblePreferredStockMember 2021-06-30 0001522767 MRMD:SeriesBConvertiblePreferredStockMember 2020-12-31 0001522767 MRMD:SeriesCConvertiblePreferredStockMember 2021-06-30 0001522767 MRMD:SeriesCConvertiblePreferredStockMember 2020-12-31 0001522767 2021-04-01 2021-06-30 0001522767 2020-04-01 2020-06-30 0001522767 2020-01-01 2020-06-30 0001522767 us-gaap:CommonStockMember 2019-12-31 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2019-12-31 0001522767 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001522767 us-gaap:RetainedEarningsMember 2019-12-31 0001522767 us-gaap:NoncontrollingInterestMember 2019-12-31 0001522767 2019-12-31 0001522767 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2020-01-01 2020-06-30 0001522767 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001522767 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001522767 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-06-30 0001522767 us-gaap:CommonStockMember 2020-06-30 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2020-06-30 0001522767 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001522767 us-gaap:RetainedEarningsMember 2020-06-30 0001522767 us-gaap:NoncontrollingInterestMember 2020-06-30 0001522767 2020-06-30 0001522767 us-gaap:CommonStockMember 2020-12-31 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2020-12-31 0001522767 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001522767 us-gaap:RetainedEarningsMember 2020-12-31 0001522767 us-gaap:NoncontrollingInterestMember 2020-12-31 0001522767 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2021-01-01 2021-06-30 0001522767 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001522767 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001522767 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-06-30 0001522767 us-gaap:CommonStockMember 2021-06-30 0001522767 MRMD:CommonStockSubscribedButNotIssuedMember 2021-06-30 0001522767 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001522767 us-gaap:RetainedEarningsMember 2021-06-30 0001522767 us-gaap:NoncontrollingInterestMember 2021-06-30 0001522767 MRMD:MariMedAdvisorsIncMember 2021-06-30 0001522767 MRMD:MiaDevelopmentLLCMember 2021-06-30 0001522767 MRMD:MariHoldingsILLLCMember 2021-06-30 0001522767 MRMD:MariHoldingsMDLLCMember 2021-06-30 0001522767 MRMD:MariHoldingsNVLLCMember 2021-06-30 0001522767 MRMD:MariHoldingsMetropolisLLCMember 2021-06-30 0001522767 MRMD:MariHoldingsMountVernonLLCMember 2021-06-30 0001522767 MRMD:HartwellRealtyHoldingsLLCMember 2021-06-30 0001522767 MRMD:IRollieLLCMember 2021-06-30 0001522767 MRMD:ARLHealthcareIncMember 2021-06-30 0001522767 MRMD:KPGOfAnnaLLCMember 2021-06-30 0001522767 MRMD:KPGofHarrisburgLLCMember 2021-06-30 0001522767 MRMD:MariMedHempIncMember 2021-06-30 0001522767 MRMD:MeditaurusLLCMember 2021-06-30 0001522767 us-gaap:AccountsReceivableMember 2021-06-30 0001522767 us-gaap:AccountsReceivableMember 2020-12-31 0001522767 us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-06-30 0001522767 MRMD:TenantImprovementsMember 2021-01-01 2021-06-30 0001522767 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2021-01-01 2021-06-30 0001522767 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2021-01-01 2021-06-30 0001522767 us-gaap:MachineryAndEquipmentMember 2021-01-01 2021-06-30 0001522767 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-01-01 2021-06-30 0001522767 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-01-01 2021-06-30 0001522767 us-gaap:MeasurementInputExpectedTermMember 2020-01-01 2020-06-30 0001522767 srt:MinimumMember 2021-06-30 0001522767 srt:MaximumMember 2021-06-30 0001522767 srt:MinimumMember 2020-06-30 0001522767 srt:MaximumMember 2020-06-30 0001522767 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001522767 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001522767 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001522767 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001522767 MRMD:SeriesBPreferredStocksMember 2021-01-01 2021-06-30 0001522767 MRMD:SeriesBPreferredStocksMember 2020-01-01 2020-06-30 0001522767 MRMD:SeriesCPreferredStocksMember 2021-01-01 2021-06-30 0001522767 MRMD:SeriesCPreferredStocksMember 2020-01-01 2020-06-30 0001522767 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-06-30 0001522767 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-06-30 0001522767 MRMD:PromissoryNotesMember 2021-01-01 2021-06-30 0001522767 MRMD:PromissoryNotesMember 2020-01-01 2020-06-30 0001522767 MRMD:CommonStocksMember 2021-04-01 2021-06-30 0001522767 MRMD:CommonStocksMember 2021-01-01 2021-06-30 0001522767 MRMD:TheHarvestFoundationLLCMember 2019-08-31 0001522767 MRMD:TwoOwnersMember MRMD:TheHarvestFoundationLLCMember 2019-08-01 2019-08-31 0001522767 MRMD:TwoOwnersMember MRMD:TheHarvestFoundationLLCMember 2019-08-31 0001522767 MRMD:KindTherapeuticsUSAIncMember 2016-12-31 0001522767 MRMD:MembersKindTherapeuticsUSAIncMember 2016-12-31 0001522767 MRMD:KindTherapeuticsUSAIncMember 2018-12-21 0001522767 MRMD:KindTherapeuticsUSAIncMember 2018-12-01 2018-12-31 0001522767 MRMD:KindTherapeuticsUSAIncMember 2018-12-31 0001522767 MRMD:KindTherapeuticsUSAIncMember MRMD:AnneArundelCountyMDMember 2019-10-31 0001522767 MRMD:MeditaurusLLCMember 2019-12-31 0001522767 MRMD:MeditaurusLLCMember 2019-12-29 2019-12-31 0001522767 MRMD:MeditaurusLLCMember 2021-01-01 2021-06-30 0001522767 MRMD:TerraceIncMember 2021-06-30 0001522767 MRMD:TerraceIncMember 2020-12-31 0001522767 MRMD:MembersRSVPLLCMember 2021-06-30 0001522767 MRMD:MembersRSVPLLCMember 2020-12-31 0001522767 MRMD:TerraceIncMember 2020-12-31 0001522767 MRMD:TerraceIncMember 2020-12-01 2020-12-31 0001522767 MRMD:TerraceIncMember 2021-01-01 2021-06-30 0001522767 MRMD:TerraceIncMember 2020-01-01 2020-06-30 0001522767 MRMD:MembersRSVPLLCMember 2018-08-31 0001522767 MRMD:MembersRSVPLLCMember 2018-08-01 2018-08-31 0001522767 MRMD:MembersRSVPLLCMember 2020-01-01 2020-06-30 0001522767 MRMD:MembersRSVPLLCMember 2021-01-01 2021-01-31 0001522767 MRMD:MembersRSVPLLCMember 2021-01-31 0001522767 stpr:DE 2016-09-30 0001522767 stpr:DE 2021-01-01 2021-06-30 0001522767 stpr:MD 2017-01-31 0001522767 stpr:MD 2021-01-01 2021-06-30 0001522767 stpr:MA MRMD:NonCannabisMember 2021-06-30 0001522767 stpr:MA MRMD:NonCannabisMember 2021-01-01 2021-06-30 0001522767 stpr:DE MRMD:RetailSpaceMember 2021-06-30 0001522767 stpr:DE MRMD:RetailSpaceMember 2021-01-01 2021-06-30 0001522767 stpr:DE MRMD:CultivationAndProcessingFacilityMember 2021-06-30 0001522767 stpr:DE MRMD:CultivationAndProcessingFacilityMember 2021-01-01 2021-06-30 0001522767 stpr:DE MRMD:CannabisProductionFacilityMember 2021-06-30 0001522767 stpr:DE MRMD:CannabisProductionFacilityMember 2021-01-01 2021-06-30 0001522767 2020-01-01 2020-12-31 0001522767 MRMD:FirstStateCompassionCenterMember 2021-06-30 0001522767 MRMD:FirstStateCompassionCenterMember 2020-12-31 0001522767 MRMD:HealerLLCMember 2021-06-30 0001522767 MRMD:HealerLLCMember 2020-12-31 0001522767 MRMD:HighFidelityIncMember 2021-06-30 0001522767 MRMD:HighFidelityIncMember 2020-12-31 0001522767 MRMD:DelawareCannabisLicenseeMember 2016-05-01 2016-05-31 0001522767 MRMD:DelawareCannabisLicenseeMember 2016-05-31 0001522767 MRMD:DelawareCannabisLicenseeMember 2021-06-30 0001522767 MRMD:DelawareCannabisLicenseeMember 2020-12-31 0001522767 MRMD:HealerLLCMember MRMD:DrDustinSulakMember 2018-01-01 2018-12-31 0001522767 MRMD:HealerLLCMember MRMD:DrDustinSulakMember 2019-01-01 2019-12-31 0001522767 MRMD:HealerLLCMember MRMD:DrDustinSulakMember 2018-12-31 0001522767 MRMD:HealerLLCMember MRMD:DrDustinSulakMember 2019-12-31 0001522767 MRMD:HealerMember 2021-03-31 0001522767 MRMD:HealerLLCMember 2021-03-31 0001522767 MRMD:HealerLLCMember 2021-06-01 2021-06-30 0001522767 MRMD:HealerLLCMember MRMD:HealerMember 2021-03-01 2021-03-31 0001522767 MRMD:HealerLLCMember MRMD:HealerMember 2021-03-31 0001522767 MRMD:PromissoryNotesMember 2021-06-30 0001522767 MRMD:PromissoryNotesMember 2020-12-30 0001522767 MRMD:HighFidelityIncMember 2019-08-31 0001522767 MRMD:MarylandHealthAndWellnessCenterIncMember MRMD:ConstructionLoanMember 2019-12-31 0001522767 us-gaap:LandMember 2021-06-30 0001522767 us-gaap:LandMember 2020-12-31 0001522767 MRMD:BuildingsandBuildingImprovementsMember 2021-06-30 0001522767 MRMD:BuildingsandBuildingImprovementsMember 2020-12-31 0001522767 MRMD:TenantImprovementsMember 2021-06-30 0001522767 MRMD:TenantImprovementsMember 2020-12-31 0001522767 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001522767 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001522767 us-gaap:MachineryAndEquipmentMember 2021-06-30 0001522767 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001522767 us-gaap:ConstructionInProgressMember 2021-06-30 0001522767 us-gaap:ConstructionInProgressMember 2020-12-31 0001522767 2020-07-01 2020-12-31 0001522767 MRMD:MilfordDeAndAnnapolisMDMember 2021-06-30 0001522767 MRMD:MilfordDeAndAnnapolisMDMember 2020-12-31 0001522767 MRMD:CannabisLicensesMember 2021-06-30 0001522767 MRMD:CannabisLicensesMember 2020-12-31 0001522767 MRMD:MortgageMember MRMD:BankOfNewEnglandMassachusettsPropertyMember 2021-06-30 0001522767 MRMD:MortgageMember MRMD:BankOfNewEnglandMassachusettsPropertyMember 2020-12-31 0001522767 MRMD:MortgageMember MRMD:BankOfNewEnglandDelawarePropertyMember 2021-06-30 0001522767 MRMD:MortgageMember MRMD:BankOfNewEnglandDelawarePropertyMember 2020-12-31 0001522767 MRMD:MortgageMember MRMD:DuQuoinStateBankIllinoisPropertiesMember 2021-06-30 0001522767 MRMD:MortgageMember MRMD:DuQuoinStateBankIllinoisPropertiesMember 2020-12-31 0001522767 MRMD:MortgageMember MRMD:SouthPorteBankIllinoisPropertyMember 2021-06-30 0001522767 MRMD:MortgageMember MRMD:SouthPorteBankIllinoisPropertyMember 2020-12-31 0001522767 MRMD:MortgageMember 2021-06-30 0001522767 MRMD:MortgageMember 2020-12-31 0001522767 MRMD:MortgageAgreementMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember MRMD:NewBedfordMassachusettsMember 2017-11-30 0001522767 MRMD:MortgageAgreementMember us-gaap:PrimeRateMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember MRMD:FloorRateMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember us-gaap:PrimeRateMember 2019-05-01 2019-05-02 0001522767 MRMD:MortgageAgreementMember MRMD:FloorRateMember 2019-05-01 2019-05-02 0001522767 MRMD:RefinancedMortgageMember 2020-07-31 0001522767 MRMD:RefinancedMortgageMember 2020-07-30 2020-07-31 0001522767 MRMD:RefinancedMortgageMember 2021-06-30 0001522767 MRMD:RefinancedMortgageMember 2020-12-31 0001522767 MRMD:MortgageAgreementMember stpr:DE 2017-11-30 0001522767 MRMD:MortgageAgreementMember stpr:DE 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember stpr:DE MRMD:SeptemberTwoThousandTwentyOneMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember stpr:DE us-gaap:PrimeRateMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember stpr:DE MRMD:FloorRateMember 2017-11-01 2017-11-30 0001522767 MRMD:MortgageAgreementMember stpr:DE 2021-06-30 0001522767 MRMD:MortgageAgreementMember stpr:DE 2020-12-31 0001522767 MRMD:MortgageAgreementMember MRMD:DuQuoinStateBankMember 2016-05-31 0001522767 MRMD:MortgageAgreementMember MRMD:DuQuoinStateBankMember 2016-05-01 2016-05-31 0001522767 MRMD:MortgageAgreementMember MRMD:DuQuoinStateBankMember 2021-06-30 0001522767 MRMD:MortgageAgreementMember MRMD:DuQuoinStateBankMember 2020-12-31 0001522767 MRMD:MortgageAgreementMember MRMD:SouthPorteBankMember 2020-02-01 2020-02-29 0001522767 MRMD:MortgageAgreementMember MRMD:SouthPorteBankMember 2020-02-27 2020-02-29 0001522767 MRMD:ExchangeAgreementMember MRMD:FourPointFourMillionNotesMember 2020-02-29 0001522767 MRMD:ExchangeAgreementMember MRMD:FourPointFourMillionNotesMember 2020-02-01 2020-02-29 0001522767 MRMD:ExchangeAgreementMember MRMD:FourPointFourMillionNotesMember 2020-12-31 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:TenMillionNoteMember 2019-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:TenMillionNoteMember 2019-06-01 2019-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:TenMillionNoteMember 2019-01-01 2019-12-31 0001522767 MRMD:PromissoryNoteMember MRMD:ElevenPointFiveMillionNoteMember 2020-02-27 2020-02-29 0001522767 MRMD:PromissoryNoteMember MRMD:ElevenPointFiveMillionNoteMember 2020-02-29 0001522767 MRMD:PromissoryNoteMember MRMD:ElevenPointFiveMillionNoteMember srt:MinimumMember 2020-02-27 2020-02-29 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:ElevenPointFiveMillionNoteMember 2020-06-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:ElevenPointFiveMillionNoteMember 2020-06-01 2020-06-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:EightPointEightMillionNoteMember 2020-06-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:EightPointEightMillionNoteMember 2021-01-01 2021-09-30 0001522767 MRMD:SecondAmendmentAgreementMember MRMD:EightPointEightMillionNoteMember 2020-06-01 2020-06-30 0001522767 MRMD:EightPointEightMillionNoteMember 2020-07-01 2020-07-31 0001522767 MRMD:EightPointEightMillionNoteMember 2020-07-31 0001522767 MRMD:EightPointEightMillionNoteMember 2020-12-31 0001522767 MRMD:EightPointEightMillionNoteMember 2021-03-31 0001522767 MRMD:EightPointEightMillionNoteMember 2021-03-01 2021-03-31 0001522767 MRMD:ThirdAmendmentAgreementMember MRMD:ThreePointTwoMillionNoteMember MRMD:RestatedPromissoryNoteMember 2021-04-30 0001522767 MRMD:ThirdAmendmentAgreementMember MRMD:ThreePointTwoMillionNoteMember 2021-04-02 2021-04-30 0001522767 MRMD:ThirdAmendmentAgreementMember MRMD:ThreePointTwoMillionNoteMember MRMD:RestatedPromissoryNoteMember 2021-04-02 2021-04-30 0001522767 MRMD:ThreePointTwoMillionNoteMember 2021-04-01 2021-06-30 0001522767 MRMD:ThreePointTwoMillionNoteMember 2021-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:GenCannaMember MRMD:OneMillionNoteMember 2019-04-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:GenCannaMember MRMD:OneMillionNoteMember 2019-04-01 2019-04-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember MRMD:NoteHolderMember MRMD:OneMillionNoteMember 2019-04-01 2019-04-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:MariMedHempIncMember 2020-12-01 2020-12-31 0001522767 MRMD:OneMillionNoteMember 2020-12-31 0001522767 MRMD:HadronHealthcareMasterFundMember MRMD:SecuredPromissoryNotesMember 2021-03-31 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:SixMillionNoteMember 2019-03-01 2019-03-31 0001522767 MRMD:ExtensionAgreementMember MRMD:NineHundredKNoteMember 2020-04-01 2020-04-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:SixMillionNoteMember 2019-01-01 2019-12-31 0001522767 MRMD:ExtensionAgreementMember MRMD:SixMillionNoteMember 2020-04-30 0001522767 MRMD:ExtensionAgreementMember MRMD:SixMillionNoteMember 2020-04-01 2020-04-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:SixMillionNoteMember 2019-03-30 0001522767 MRMD:ExtensionAgreementMember MRMD:NineHundredKNoteMember 2020-04-30 0001522767 MRMD:ExtensionAgreementMember MRMD:NineHundredKNoteMember 2020-07-31 0001522767 MRMD:ExtensionAgreementMember 2020-06-01 2020-06-30 0001522767 MRMD:SecuredPromissoryNotesMember MRMD:ThreeMillionNoteMember 2018-09-01 2018-09-30 0001522767 MRMD:PromissoryNotesMember MRMD:ThreeMillionNoteMember 2018-09-30 0001522767 MRMD:SecondExtensionAgreementMember MRMD:PromissoryNotesMember MRMD:SixPointEightMillionNoteMember 2020-10-31 0001522767 MRMD:SecondExtensionAgreementMember MRMD:PromissoryNotesMember MRMD:SixPointEightMillionNoteMember 2020-10-30 2020-10-31 0001522767 MRMD:SecondExtensionAgreementMember MRMD:PromissoryNotesMember MRMD:FivePointEightMillionNoteMember 2020-10-31 0001522767 MRMD:ThirdAmendmentAgreementMember MRMD:PromissoryNotesMember 2020-10-30 2020-10-31 0001522767 MRMD:SecondExtensionAgreementMember MRMD:PromissoryNotesMember 2020-10-31 0001522767 2020-10-29 2020-10-31 0001522767 MRMD:SecondExtensionAgreementMember MRMD:PromissoryNotesMember 2020-10-01 2020-10-31 0001522767 MRMD:SecondExtensionAgreementMember MRMD:PromissoryNotesMember 2020-12-31 0001522767 MRMD:SecondExtensionAgreementMember MRMD:PromissoryNotesMember MRMD:FivePointEightMillionNoteMember MRMD:FebruaryTwoThousandTwentyOneMember 2020-10-01 2020-10-31 0001522767 MRMD:PromissoryNoteMember MRMD:FivePointEightMillionNoteMember 2021-01-01 2021-03-31 0001522767 MRMD:FirstCitizensFederalCreditUnionMember MRMD:PromissoryNotesMember 2020-10-30 2020-10-31 0001522767 MRMD:FirstCitizensFederalCreditUnionMember MRMD:PromissoryNotesMember 2020-08-01 2020-08-31 0001522767 MRMD:FirstCitizensFederalCreditUnionMember MRMD:PromissoryNotesMember 2021-06-30 0001522767 MRMD:FirstCitizensFederalCreditUnionMember MRMD:PromissoryNotesMember 2020-12-31 0001522767 MRMD:NoteAgreementMember 2021-06-01 2021-06-30 0001522767 MRMD:NoteAgreementMember 2021-06-30 0001522767 MRMD:ExistingNotesMember 2020-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember srt:MinimumMember 2020-01-01 2020-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember srt:MaximumMember 2020-01-01 2020-12-31 0001522767 MRMD:NewPromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember 2020-01-01 2020-12-31 0001522767 MRMD:NewPromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember srt:MinimumMember 2020-01-01 2020-12-31 0001522767 MRMD:NewPromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember srt:MaximumMember 2020-01-01 2020-12-31 0001522767 MRMD:ExistingNotesMember MRMD:IndividualsAndAccreditedInvestorsMember 2020-01-01 2020-12-31 0001522767 MRMD:ExistingNotesMember 2020-01-01 2020-12-31 0001522767 MRMD:PromissoryNotesMember MRMD:IndividualsAndAccreditedInvestorsMember 2020-12-31 0001522767 MRMD:ExistingNotesandNewPromissoryNotesMember 2020-12-31 0001522767 MRMD:ExistingNotesandNewPromissoryNotesMember 2020-01-01 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2020-02-29 0001522767 MRMD:ConvertibleDebenturesOneMember 2021-01-01 2021-06-30 0001522767 MRMD:ConvertibleDebenturesOneMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesTwoMember 2021-01-01 2021-06-30 0001522767 MRMD:ConvertibleDebenturesTwoMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesThreeMember 2021-01-01 2021-06-30 0001522767 MRMD:ConvertibleDebenturesThreeMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesFourMember 2021-01-01 2021-06-30 0001522767 MRMD:ConvertibleDebenturesFourMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesFiveMember 2021-01-01 2021-06-30 0001522767 MRMD:ConvertibleDebenturesFiveMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesSixMember 2021-01-01 2021-06-30 0001522767 MRMD:ConvertibleDebenturesSixMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:HolderMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:HolderMember 2021-01-01 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:HolderMember srt:MinimumMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:HolderMember srt:MaximumMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember 2020-01-01 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember srt:MinimumMember 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember srt:MaximumMember 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember 2021-01-01 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember srt:MinimumMember 2021-06-30 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2020-01-01 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember MRMD:WarrantsMember 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember MRMD:WarrantsMember srt:MinimumMember 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember MRMD:WarrantsMember srt:MaximumMember 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2020-12-31 0001522767 MRMD:ConvertibleDebenturesMember MRMD:TwentyOneMillionHolderMember 2021-01-01 2021-06-30 0001522767 MRMD:TwentyOneMillionHolderMember 2020-12-31 0001522767 MRMD:ExchangeAgreementMember MRMD:TwoInstitutionalShareholdersMember MRMD:SeriesBConvertiblePreferredStockMember 2020-02-01 2020-02-29 0001522767 MRMD:SeriesBHoldersMember 2020-02-29 0001522767 MRMD:SeriesBConvertiblePreferredStockMember MRMD:VolumeWeightedAveragepriceOfCommonStockMember 2020-02-29 0001522767 MRMD:SeriesBConvertiblePreferredStockMember MRMD:VolumeWeightedAveragepriceOfCommonStockMember 2020-02-01 2020-02-29 0001522767 MRMD:SeriesBConvertiblePreferredStockMember MRMD:VolumeWeightedAveragepriceOfCommonStockMember 2020-02-28 2020-02-29 0001522767 MRMD:SecuritiesPurchaseAgreementMember MRMD:HadronHealthcareMasterFundMember srt:MaximumMember 2021-03-01 2021-03-31 0001522767 MRMD:SecuritiesPurchaseAgreementMember MRMD:HadronHealthcareMasterFundMember 2021-03-01 2021-03-31 0001522767 MRMD:SecuritiesPurchaseAgreementMember MRMD:HadronHealthcareMasterFundMember 2021-03-31 0001522767 MRMD:HadronHealthcareMasterFundMember MRMD:WarrantsMember 2021-03-01 2021-03-31 0001522767 MRMD:HadronHealthcareMasterFundMember MRMD:WarrantsMember srt:MaximumMember 2021-03-31 0001522767 MRMD:HadronHealthcareMasterFundMember MRMD:WarrantsMember 2021-03-31 0001522767 MRMD:WarrantsTwoMember 2021-01-01 2021-03-31 0001522767 2021-03-01 2021-03-31 0001522767 MRMD:ThreeMillionNoteMember 2021-01-01 2021-06-30 0001522767 MRMD:SeriesCConvertiblePreferredStockMember srt:MinimumMember 2021-03-01 2021-03-31 0001522767 MRMD:SeriesBConvertiblePreferredStockMember MRMD:ExchangeAgreementMember MRMD:TwoInstitutionalShareholdersMember 2020-02-29 0001522767 MRMD:CommonStocksMember 2021-01-01 2021-06-30 0001522767 MRMD:CommonStocksMember 2020-01-01 2020-06-30 0001522767 MRMD:PreviouslyIssuedSubscriptionMember 2021-01-01 2021-06-30 0001522767 MRMD:PreviouslyIssuedSubscriptionMember 2020-01-01 2020-06-30 0001522767 MRMD:PromissoryNotesMember 2021-01-01 2021-06-30 0001522767 MRMD:PromissoryNotesMember 2020-06-01 2020-06-30 0001522767 MRMD:PromissoryNotesMember 2020-06-30 0001522767 MRMD:PromissoryNoteMember 2020-06-01 2020-06-30 0001522767 MRMD:TwentyOneMillionHoldersMember 2021-06-30 0001522767 MRMD:TwentyOneMillionHoldersMember 2021-01-01 2021-06-30 0001522767 MRMD:TwentyOneMillionHoldersMember 2020-12-31 0001522767 MRMD:TwentyOneMillionHoldersMember 2020-01-01 2020-12-31 0001522767 MRMD:OptionsMember 2021-01-01 2021-06-30 0001522767 MRMD:OptionsMember 2020-01-01 2020-06-30 0001522767 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001522767 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001522767 MRMD:CommonStockIssuanceObligationsMember 2020-01-01 2020-06-30 0001522767 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-01-01 2021-06-30 0001522767 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-06-30 0001522767 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001522767 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-06-30 0001522767 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001522767 MRMD:EmployeeStockOptionOneMember 2021-01-01 2021-06-30 0001522767 MRMD:EmployeeStockOptionOneMember srt:MinimumMember 2021-01-01 2021-06-30 0001522767 MRMD:EmployeeStockOptionOneMember srt:MaximumMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeOneMember 2021-06-30 0001522767 MRMD:RangeOneMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwoMember 2021-06-30 0001522767 MRMD:RangeTwoMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThreeMember 2021-06-30 0001522767 MRMD:RangeThreeMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeFourMember 2021-06-30 0001522767 MRMD:RangeFourMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeFiveMember 2021-06-30 0001522767 MRMD:RangeFiveMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeSixMember 2021-06-30 0001522767 MRMD:RangeSixMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeSevenMember 2021-06-30 0001522767 MRMD:RangeSevenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeEightMember 2021-06-30 0001522767 MRMD:RangeEightMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeNineMember 2021-06-30 0001522767 MRMD:RangeNineMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTenMember 2021-06-30 0001522767 MRMD:RangeTenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeElevenMember 2021-06-30 0001522767 MRMD:RangeElevenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwelveMember 2021-06-30 0001522767 MRMD:RangeTwelveMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirteenMember 2021-06-30 0001522767 MRMD:RangeThirteenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeFourteenMember 2021-06-30 0001522767 MRMD:RangeFourteenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeFifteenMember 2021-06-30 0001522767 MRMD:RangeFifteenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeSixteenMember 2021-06-30 0001522767 MRMD:RangeSixteenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeSeventeenMember 2021-06-30 0001522767 MRMD:RangeSeventeenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeEighteenMember 2021-06-30 0001522767 MRMD:RangeEighteenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeNineteenMember 2021-06-30 0001522767 MRMD:RangeNineteenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentyMember 2021-06-30 0001522767 MRMD:RangeTwentyMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentyOneMember 2021-06-30 0001522767 MRMD:RangeTwentyOneMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentyTwoMember 2021-06-30 0001522767 MRMD:RangeTwentyTwoMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentyThreeMember 2021-06-30 0001522767 MRMD:RangeTwentyThreeMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentyFourMember 2021-06-30 0001522767 MRMD:RangeTwentyFourMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentyFiveMember 2021-06-30 0001522767 MRMD:RangeTwentyFiveMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentySixMember 2021-06-30 0001522767 MRMD:RangeTwentySixMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentySevenMember 2021-06-30 0001522767 MRMD:RangeTwentySevenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentyEightMember 2021-06-30 0001522767 MRMD:RangeTwentyEightMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeTwentyNineMember 2021-06-30 0001522767 MRMD:RangeTwentyNineMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtyMember 2021-06-30 0001522767 MRMD:RangeThirtyMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtyOneMember 2021-06-30 0001522767 MRMD:RangeThirtyOneMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtyTwoMember 2021-06-30 0001522767 MRMD:RangeThirtyTwoMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtyThreeMember 2021-06-30 0001522767 MRMD:RangeThirtyThreeMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtyFourMember 2021-06-30 0001522767 MRMD:RangeThirtyFourMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtyFiveMember 2021-06-30 0001522767 MRMD:RangeThirtyFiveMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtySixMember 2021-06-30 0001522767 MRMD:RangeThirtySixMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtySevenMember 2021-06-30 0001522767 MRMD:RangeThirtySevenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtyEighteenMember 2021-06-30 0001522767 MRMD:RangeThirtyEighteenMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeThirtyNineMember 2021-06-30 0001522767 MRMD:RangeThirtyNineMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeFourtyMember 2021-06-30 0001522767 MRMD:RangeFourtyMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeFourtyOneMember 2021-06-30 0001522767 MRMD:RangeFourtyOneMember 2021-01-01 2021-06-30 0001522767 MRMD:RangeFourtyTwoMember 2021-06-30 0001522767 MRMD:RangeFourtyTwoMember 2021-01-01 2021-06-30 0001522767 MRMD:WarrantsOneMember 2021-06-30 0001522767 MRMD:WarrantsOneMember srt:MinimumMember 2021-06-30 0001522767 MRMD:WarrantsOneMember srt:MaximumMember 2021-06-30 0001522767 MRMD:WarrantsOneMember 2021-01-01 2021-06-30 0001522767 MRMD:WarrantsTwoMember 2021-06-30 0001522767 MRMD:WarrantsTwoMember 2021-01-01 2021-06-30 0001522767 MRMD:DebenturePayableMember 2020-06-30 0001522767 MRMD:EightPointEightMillionMember 2020-06-30 0001522767 MRMD:DebenturePayableMember 2020-01-01 2020-06-30 0001522767 MRMD:WarrantExercisedMember 2021-06-30 0001522767 MRMD:WarrantExercisedMember srt:MinimumMember 2021-06-30 0001522767 MRMD:WarrantExercisedMember srt:MaximumMember 2021-06-30 0001522767 MRMD:WarrantForfeitedMember 2021-06-30 0001522767 MRMD:WarrantForfeitedMember srt:MinimumMember 2021-06-30 0001522767 MRMD:WarrantForfeitedMember srt:MaximumMember 2021-06-30 0001522767 MRMD:ProductSalesMember 2021-01-01 2021-06-30 0001522767 MRMD:ProductSalesMember 2020-01-01 2020-06-30 0001522767 MRMD:ProductSalesWholesaleMember 2021-01-01 2021-06-30 0001522767 us-gaap:RealEstateMember 2021-01-01 2021-06-30 0001522767 us-gaap:RealEstateMember 2020-01-01 2020-06-30 0001522767 us-gaap:ManagementServiceMember 2021-01-01 2021-06-30 0001522767 us-gaap:ManagementServiceMember 2020-01-01 2020-06-30 0001522767 MRMD:SupplyProcurementMember 2021-01-01 2021-06-30 0001522767 MRMD:SupplyProcurementMember 2020-01-01 2020-06-30 0001522767 us-gaap:LicenseAndServiceMember 2021-01-01 2021-06-30 0001522767 us-gaap:LicenseAndServiceMember 2020-01-01 2020-06-30 0001522767 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember MRMD:TwoClientsMember 2021-04-01 2021-06-30 0001522767 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember MRMD:TwoClientsMember 2020-04-01 2020-06-30 0001522767 MRMD:ARAllowanceMember 2021-06-30 0001522767 MRMD:ARAllowanceMember 2021-01-01 2021-06-30 0001522767 MRMD:ARAllowanceMember 2020-06-30 0001522767 MRMD:COOMember us-gaap:CommonStockMember 2020-04-01 2020-04-30 0001522767 MRMD:COOMember 2020-04-30 0001522767 MRMD:COOMember 2020-04-01 2020-04-30 0001522767 MRMD:CEOAndCFOAndIndependentBoardMemberMember us-gaap:CommonStockMember 2020-12-03 2020-12-31 0001522767 srt:MinimumMember MRMD:CEOAndCFOAndIndependentBoardMemberMember MRMD:OptionsMember 2020-12-31 0001522767 srt:MaximumMember MRMD:CEOAndCFOAndIndependentBoardMemberMember MRMD:OptionsMember 2020-12-31 0001522767 srt:ChiefOperatingOfficerMember 2021-01-01 2021-06-30 0001522767 srt:ChiefOperatingOfficerMember 2020-01-01 2020-06-30 0001522767 MRMD:BettysEddiesProductsMember MRMD:RoyaltyAgreementMember 2021-01-01 2021-06-30 0001522767 MRMD:BettysEddiesProductsMember MRMD:RoyaltyAgreementMember 2021-06-30 0001522767 MRMD:BettysEddiesProductsMember MRMD:RoyaltyAgreementMember 2020-06-30 0001522767 MRMD:CEOandCFOMember 2021-01-01 2021-06-30 0001522767 MRMD:CEOandCFOMember 2020-01-01 2020-06-30 0001522767 MRMD:EmployeeMember 2021-01-01 2021-06-30 0001522767 MRMD:EmployeeMember 2020-01-01 2020-06-30 0001522767 MRMD:CEOMember 2020-12-31 0001522767 MRMD:CEOandCFOMember MRMD:OwnedCompaniesMember 2020-12-31 0001522767 MRMD:StockholdersMember 2020-12-31 0001522767 stpr:DE MRMD:OperatingLeaseCommitmentsMember 2021-06-30 0001522767 stpr:DE MRMD:OperatingLeaseCommitmentsMember 2021-01-01 2021-06-30 0001522767 stpr:DE 2021-06-30 0001522767 stpr:DE MRMD:ThreeAdditionalFiveYearPeriodsMember 2021-01-01 2021-06-30 0001522767 stpr:DE MRMD:CannabisProductionFacilityMember 2021-06-30 0001522767 stpr:DE MRMD:CannabisProductionFacilityMember 2021-01-01 2021-06-30 0001522767 stpr:NV 2021-06-30 0001522767 stpr:NV 2021-01-01 2021-06-30 0001522767 stpr:MA 2021-06-30 0001522767 stpr:MA 2021-01-01 2021-06-30 0001522767 stpr:MD MRMD:OperatingLeaseCommitmentsMember 2021-06-30 0001522767 stpr:MD MRMD:OperatingLeaseCommitmentsMember 2021-01-01 2021-06-30 0001522767 MRMD:FinanceLeaseCommitmentsMember MRMD:MachineryAndOfficeEquipmentMember 2021-01-01 2021-06-30 0001522767 MRMD:LeaseCommitmentsMember 2021-06-30 0001522767 MRMD:LeaseCommitmentsMember srt:MinimumMember 2021-06-30 0001522767 MRMD:LeaseCommitmentsMember srt:MaximumMember 2021-06-30 0001522767 MRMD:OperatingLeasesMember 2021-06-30 0001522767 MRMD:FinancingLeasesMember 2021-06-30 0001522767 MRMD:TerminatedEmploymentAgreementMember 2021-06-30 0001522767 MRMD:TerminatedEmploymentAgreementMember 2020-12-31 0001522767 MRMD:MarylandAcquisitionMember 2019-11-01 2019-11-30 0001522767 MRMD:GenCannaGlobalIncMember 2019-12-31 0001522767 MRMD:OGGUSADebtorsMember 2020-05-01 2020-05-31 0001522767 MRMD:OGGUSADebtorsMember 2020-05-31 0001522767 us-gaap:SubsequentEventMember 2021-07-01 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:MetropolisPropertyMember 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:DuQuoinStateBankMember 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:DuQuoinStateBankMember 2021-07-01 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:MariHoldingsMetropolisLLCMember 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember 2021-06-29 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember 2021-06-29 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefFinancialOfficerMember 2021-06-29 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefOperatingOfficerMember 2021-06-29 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember MRMD:NonQualifiedStockOptionsMember 2021-06-29 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefFinancialOfficerMember MRMD:NonQualifiedStockOptionsMember 2021-06-29 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefOperatingOfficerMember MRMD:NonQualifiedStockOptionsMember 2021-06-29 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember MRMD:NonQualifiedStockOptionsMember 2021-06-29 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefExecutiveOfficerMember MRMD:NonQualifiedStockOptionsMember 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefFinancialOfficerMember MRMD:NonQualifiedStockOptionsMember 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:EmploymentAgreementMember srt:ChiefOperatingOfficerMember MRMD:NonQualifiedStockOptionsMember 2021-07-02 0001522767 us-gaap:SubsequentEventMember MRMD:ThreePointTwoMillionNoteMember MRMD:NoteHolderMember 2021-08-31 0001522767 us-gaap:SubsequentEventMember MRMD:ThreePointTwoMillionNoteMember MRMD:NoteHolderMember 2021-08-01 2021-08-31 0001522767 2021-07-01 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:EmployeesMember 2021-07-01 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:EmployeesMember 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:IndependentBoardMembersMember 2021-07-01 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:EmployeesMember srt:MinimumMember 2021-07-01 2021-07-31 0001522767 us-gaap:SubsequentEventMember MRMD:EmployeesMember srt:MaximumMember 2021-07-01 2021-07-31 0001522767 us-gaap:SubsequentEventMember srt:MinimumMember 2021-07-01 2021-07-31 0001522767 us-gaap:SubsequentEventMember srt:MaximumMember 2021-07-01 2021-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period ended June 30, 2021

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________________ to __________________

 

Commission File number 0-54433

 

MARIMED INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   27-4672745
(State or Other Jurisdiction of   (I.R.S. Employer
Incorporation or Organization)   Identification No.)

 

10 Oceana Way

Norwood, MA 02062

(Address of Principal Executive Offices)

 

617-795-5140

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
Not Applicable.   Not Applicable.   Not Applicable.

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of August 16, 2021, 329,143,662 shares of the registrant’s common stock were outstanding.

 

 

 

 

 

 

MariMed Inc.

Table of Contents

 

    Page
  PART I – FINANCIAL INFORMATION  
     
Item 1. Financial Statements  
     
  Condensed Consolidated Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020 3
     
  Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 (Unaudited) 4
     
  Condensed Consolidated Statements of Stockholders’ Equity for the Six Months Ended June 30, 2021 and 2020 (Unaudited) 5
     
  Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (Unaudited) 6
     
  Notes to Condensed Consolidated Financial Statements (Unaudited) 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 36
     
Item 3. Quantitative and Qualitative Disclosure About Market Risk 43
     
Item 4. Controls and Procedures 43
     
  PART II – OTHER INFORMATION  
     
Item 1. Legal Proceedings 44
     
Item 1A. Risk Factors 44
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44
     
Item 3. Defaults Upon Senior Securities 44
     
Item 4. Mine Safety Disclosures 44
     
Item 5. Other Information 44
     
Item 6. Exhibits 45
     
Signatures 48

 

2
 

 

MariMed Inc.

Condensed Consolidated Balance Sheets

 

   2021   2020 
   June 30,   December 31, 
   2021   2020 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $17,356,525   $2,999,053 
Accounts receivable, net   8,085,867    6,675,512 
Deferred rents receivable   1,815,330    1,940,181 
Notes receivable, current portion   377,127    658,122 
Inventory   9,228,098    6,830,571 
Investments   941,910    1,357,193 
Other current assets   1,955,445    582,589 
Total current assets   39,760,302    21,043,221 
           
Property and equipment, net   52,666,031    45,636,529 
Intangibles, net   2,521,094    2,228,560 
Investments   1,165,788    1,165,788 
Notes receivable, less current portion   1,194,448    965,008 
Right-of-use assets under operating leases   5,406,601    5,247,152 
Right-of-use assets under finance leases   62,078    78,420 
Other assets   97,950    80,493 
Total assets  $102,874,292   $76,445,171 
           
Liabilities, mezzanine equity, and stockholders’ equity          
Current liabilities:          
Accounts payable  $6,693,390   $5,044,918 
Accrued expenses   8,145,061    3,621,269 
Sales and excise taxes payable   1,535,226    1,053,693 
Debentures payable   -    1,032,448 
Notes payable, current portion   9,523    8,859,175 
Mortgages payable, current portion   1,350,548    1,387,014 
Operating lease liabilities, current portion   1,118,121    1,008,227 
Finance lease liabilities, current portion   33,453    38,412 
Due to related parties   -    1,157,815 
Other current liabilities   -    23,640 
Total current liabilities   18,885,322    23,226,611 
           
Notes payable, less current portion   2,015,001    10,682,234 
Mortgages payable, less current portion   14,484,255    14,744,136 
Operating lease liabilities, less current portion   4,862,628    4,822,064 
Finance lease liabilities, less current portion   33,098    44,490 
Other liabilities   100,200    100,200 
Total liabilities   40,380,504    53,619,735 
           
Mezzanine equity:          
Series B convertible preferred stock, $0.001 par value; 4,908,333 shares authorized, issued and outstanding at June 30, 2021 and December 31, 2020   14,725,000    14,725,000 
Series C convertible preferred stock, $0.001 par value; 6,216,216 and zero shares authorized, issued and outstanding at June 30, 2021 and December 31, 2020, respectively   23,000,000    - 
Total mezzanine equity   37,725,000    14,725,000 
           
Stockholders’ equity:          
Undesignated preferred stock, $0.001 par value; 38,875,451 and 45,091,667 shares authorized at June 30, 2021 and December 31, 2020, respectively; zero shares issued and outstanding at June 30, 2021 and December 31, 2020   -    - 
Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2021 and December 31, 2020; 326,838,535 and 314,418,812 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively   326,839    314,419 
Common stock subscribed but not issued; zero and 11,413 shares at June 30, 2021 and December 31, 2020, respectively   -    5,365 
Additional paid-in capital   117,919,783    112,974,329 
Accumulated deficit   (92,903,783)   (104,616,538)
Noncontrolling interests   (574,051)   (577,139)
Total stockholders’ equity   24,768,788    8,100,436 
Total liabilities, mezzanine equity, and stockholders’ equity  $102,874,292   $76,445,171 

 

See accompanying notes to condensed consolidated financial statements.

 

3
 

 

MariMed Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

   2021   2020   2021   2020 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2021   2020   2021   2020 
                 
Revenues  $32,569,656   $9,610,306   $57,212,220   $17,076,325 
                     
Cost of revenues   13,163,306    3,452,169    24,619,952    6,050,086 
                     
Gross profit   19,406,350    6,158,137    32,592,268    11,026,239 
                     
Operating expenses:                    
Personnel   2,058,254    1,207,141    3,785,395    2,720,524 
Marketing and promotion   270,330    65,618    494,699    178,002 
General and administrative   4,282,004    2,336,102    7,452,728    4,584,037 
Bad debts   793,871    450,000    1,819,286    450,000 
Total operating expenses   7,404,459    4,058,861    13,552,108    7,932,563 
                     
Operating income   12,001,891    2,099,276    19,040,160    3,093,676 
                     
Non-operating income (expenses):                    
Interest expense   (264,596)   (2,969,191)   (1,776,618)   (5,660,336)
Interest income   35,768    40,863    69,795    86,894 
Loss on obligations settled with equity   (1,260)   (44,678)   (2,546)   (44,678)
Loss on equity investments   -    (32,958)   -    (32,958)
Change in fair value of investments   (370,119)   (234,544)   (415,284)   (921,546)
Total non-operating income (expenses), net   (600,207)   (3,240,508)   (2,124,653)   (6,572,624)
                     
Income (loss) before income taxes   11,401,684    (1,141,232)   16,915,507    (3,478,948)
Provision for income taxes   3,813,108    -    5,016,905    - 
Net income (loss)  $7,588,576   $(1,141,232)  $11,898,602   $(3,478,948)
                     
Net income (loss) attributable to noncontrolling interests  $95,724   $72,805   $185,847   $156,533 
Net income (loss) attributable to MariMed Inc.  $7,492,852   $(1,214,037)  $11,712,755   $(3,635,481)
                     
Net income (loss) per share                    
Basic  $0.02   $(0.00)  $0.04   $(0.02)
Diluted  $0.02   $(0.00)  $0.03   $(0.02)
                     
Weighted average common shares outstanding                    
Basic   324,266,644    247,990,403    321,740,575    240,664,873 
Diluted   370,256,963    247,990,403    365,323,638    240,664,873 

 

See accompanying notes to condensed consolidated financial statements.

 

4
 

 

MariMed Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

 

   Shares   Par Value   Shares   Amount   Capital   Deficit   Interests   (Deficit) 
   Common Stock  

Common Stock

Subscribed But

Not Issued

  

Additional

Paid-In

   Accumulated  

Non-

Controlling

  

Total

Stockholders’

Equity

 
   Shares   Par Value   Shares   Amount   Capital   Deficit   Interests   (Deficit) 
Balances at December 31, 2019   228,408,024   $228,408    3,236,857   $1,168,074   $112,245,730   $(106,760,527)  $(553,465)   6,328,220 
Issuance of subscribed shares   3,236,857    3,237    (3,236,857)   (1,168,074)   1,164,837    -    -    - 
Stock grants   30,307    30    34,171    5,365    5,335    -    -    10,730 
Amortization of option grants   -    -    -    -    556,379    -    -    556,379 
Issuance of warrants attached to debt   -    -    -    -    65,931    -    -    65,931 
Discount on debentures payable   -    -    -    -    28,021    -    -    28,021 
Beneficial conversion feature on debentures payable   -    -    -    -    379,183    -    -    379,183 
Conversion of debentures payable   35,886,796    35,887    -    -    4,981,208    -    -    5,017,095 
Conversion of common stock to preferred stock   (4,908,333)   (4,908)   -    -    (14,720,092)   -    -    (14,725,000)
Conversion of promissory note   2,525,596    2,525    -    -    457,525    -    -    460,050 
Extinguishment of promissory note   1,900,000    1,900    -    -    350,100    -    -    352,000 
Common stock issued to settle obligations   4,400,000    4,400    -    -    739,200    -    -    743,600 
Distributions   -    -    -    -    -    -    (166,952)   (166,952)
Net income (loss)   -    -    -    -    -    (3,635,481)   156,533    (3,478,948)
Balances at June 30, 2020   271,479,247   $  271,479    34,171   $5,365   $  106,253,357   $  (110,396,008)  $(563,884)  $(4,429,691)

 

 

   Common Stock  

Common Stock

Subscribed But

Not Issued

  

Additional

Paid-In

   Accumulated  

Non-

Controlling

  

Total

Stockholders’

 
   Shares   Par Value   Shares   Amount   Capital   Deficit   Interests   Equity 
Balances at December 31, 2020   314,418,812   $314,419    11,413   $5,365   $112,974,329   $(104,616,538)  $(577,139)   8,100,436 
Issuance of subscribed shares   11,413    11    (11,413)   (5,365)   5,354    -    -    - 
Stock grants   6,877    7    -    -    5,358    -    -    5,365 
Exercise of options   82,885    83    -    -    8,917    -    -    9,000 
Exercise of warrants   698,812    699    -    -    60,098    -    -    60,797 
Amortization of option grants   -    -    -    -    884,075    -    -    884,075 
Issuance of stand-alone warrants   -    -    -    -    55,786    -    -    55,786 
Issuance of warrants with stock   -    -    -    -    654,681    -    -    654,681 
Conversion of debentures payable   4,610,645    4,611    -    -    1,351,841    -    -    1,356,452 
Conversion of promissory notes   6,937,400    6,937    -    -    2,252,854    -    -    2,259,791 
Common stock issued to settle obligations   71,691    72    -    -    53,473    -    -    53,545 
Equity issuance costs   -    -    -    -    (386,983)   -    -    (386,983)
Distributions   -    -    -    -    -    -    (182,759)   (182,759)
Net income    -    -    -    -    -    11,712,755    185,847    11,898,602 
Balances at June 30, 2021   326,838,535   $  326,839    -   $-   $  117,919,783   $(92,903,783)  $(574,051)  $24,768,788 

 

The above statements do not show columns for undesignated preferred stock

as the balances were zero and there was no activity in the reported periods.

See accompanying notes to condensed consolidated financial statements.

 

5
 

 

MariMed Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   2021   2020 
   Six Months Ended June 30, 
   2021   2020 
Cash flows from operating activities:          
Net income (loss) attributable to MariMed Inc.  $11,712,755   $(3,635,481)
Net income (loss) attributable to noncontrolling interests   185,847    156,533 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:          
Depreciation   962,571    907,285 
Amortization of intangibles   346,036    166,908 
Amortization of stock grants   5,365    10,730 
Amortization of option grants   884,075    556,379 
Amortization of stand-alone warrant issuances   55,786    - 
Amortization of warrants attached to debt   539,272    498,694 
Amortization of warrants issued with stock   654,681    - 
Amortization of beneficial conversion feature   176,522    2,170,401 
Amortization of original issue discount   51,753    241,613 
Bad debt expense   1,819,286    450,000 
Loss on obligations settled with equity   2,546    44,678 
Equity in earnings of investments   -    32,958 
Change in fair value of investments   415,284    921,546 
Changes in operating assets and liabilities:          
Accounts receivable, net   (3,229,641)   (1,654,366)
Deferred rents receivable   124,851    (193,464)
Inventory   (2,397,527)   (2,686,534)
Other current assets   (1,372,856)   (215,413)
Other assets   (17,458)   (10,000)
Accounts payable   1,699,471    566,749 
Accrued expenses   4,522,782    1,363,094 
Sales and excise taxes payable   481,533    396,236 
Operating lease payments, net   (8,991)   51,043 
Finance lease interest payments   1,504    4,033 
Other current liabilities   (23,640)   396,236 
Net cash provided by operating activities   17,591,807    539,858 
           
Cash flows from investing activities:          
Purchase of property and equipment   (7,975,731)   (2,720,655)
Purchase of cannabis licenses   (638,570)   (255,000)
Interest on notes receivable   118,811    406,670 
Net cash used in investing activities   (8,495,490)   (2,568,985)
           
Cash flows from financing activities:          
Proceeds from issuance of preferred stock   23,000,000    - 
Equity issuance costs   (386,983)   - 
Proceeds from issuance of promissory notes   35,096    5,249,763 
Repayments of promissory notes   (15,801,979)   (3,100,000)
Proceeds from issuance of debentures   -    935,000 
Proceeds from mortgages   -    907,200 
Payments on mortgages   (296,347)   (112,352)
Proceeds from exercise of options   9,000    - 
Proceeds from exercise of warrants   60,797    - 
Due to related parties   (1,157,815)   (63,404)
Finance lease principal payments   (17,855)   (19,206)
Distributions   (182,759)   (166,952)
Net cash provided by financing activities   5,261,155    3,630,049 
           
Net change to cash and cash equivalents   14,357,472    1,600,922 
Cash and cash equivalents at beginning of period   2,999,053    738,688 
Cash and cash equivalents at end of period  $17,356,525   $2,339,610 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $1,405,489   $703,571
Cash paid for income taxes  $419,003   $13,000
           
Non-cash activities:          
Conversion of promissory notes  $2,259,791   $460,050 
Conversions of debentures payable  $1,356,452   $5,017,095 
Operating lease right-of-use assets and liabilities  $466,105   $- 
Common stock issued to settle obligations  $51,000   $698,922 
Issuance of common stock associated with subscriptions  $5,365   $1,168,074 
Cashless exercise of warrants  $180   $- 
Cashless exercise of stock options  $53   $- 
Exchange of common stock to preferred stock  $-   $14,725,000 
Conversion of accrued interest to promissory notes  $-   $3,908,654 
Beneficial conversion feature on debentures payable  $-   $379,183 
Extinguishment of promissory note  $-   $352,000 
Discount on promissory notes  $-   $65,931 
Discount on debentures payable  $-   $28,021 

  

See accompanying notes to condensed consolidated financial statements.

 

6
 

 

MariMed Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

MariMed Inc. (the “Company”) is a multi-state operator in the United States cannabis industry. The Company develops, operates, manages, and optimizes over 300,000 square feet of state-of-the-art, regulatory-compliant facilities for the cultivation, production and dispensing of medicinal and recreational cannabis. The Company also licenses its proprietary brands of cannabis and hemp-infused products, along with other top brands, in several domestic markets and overseas.

 

Upon its entry into the cannabis industry in 2014, the Company was an advisory firm that procured state-issued cannabis licenses on behalf of its clients, developed cannabis facilities which it leased to these newly-licensed companies, and provided industry-leading expertise and oversight in all aspects of their cannabis operations. The Company also provided its clients with as ongoing regulatory, accounting, real estate, human resources, and administrative services.

 

Thereafter, the Company made the strategic decision to transition from a consulting business to a direct owner and operator of cannabis licenses in high-growth states. Core to this transition is the acquisition and consolidation of the Company’s clients (the “Consolidation Plan”). Among several benefits, the Consolidation Plan would present a simpler, more transparent financial picture of the full breadth of the Company’s efforts, with a clearer representation of the revenues, earnings, and other financial metrics the Company has generated for its clients. The Company has played a key role in the successes of these entities, from the securing of their cannabis licenses, to the development of facilities that are models of excellence, to funding their operations, and to providing operational and corporate guidance. Accordingly, the Company believes it is well suited to own these facilities and manage the continuing growth of their operations.

 

To date, acquisitions of its client businesses in Massachusetts and Illinois have been completed and establish the Company as a fully integrated seed-to-sale multi-state operator (“MSO”). The acquisitions of the remaining entities located in Maryland, Nevada, and Delaware are at various stages of completion and subject to each state’s laws governing the ownership transfer of cannabis licenses, which in the case of Delaware requires a modification of current cannabis ownership laws to permit for-profit ownership. Meanwhile, the Company continues to expand these businesses and maximize the Company’s revenue from rental income, management fees, and licensing royalties.

 

The transition to becoming a fully integrated MSO is part of a strategic growth plan (the “Strategic Growth Plan”) the Company is implementing to drive its revenues and profitability. The Strategic Growth Plan has four components: (i) complete the Consolidation Plan, (ii) increase revenues in existing states, by spending capital to increase the Company’s cultivation and production capacity, and develop additional assets within those states, (iii) expand the Company’s footprint in additional legal cannabis states through new applications and acquisitions of existing cannabis businesses; and (iv) expand the Company’s brand portfolio and licensing revenue, by continuing to build its portfolio of leading brands and license its brands in other legal states.

 

As to its products, the Company has created its own brands of cannabis flower, concentrates, and precision-dosed products utilizing proprietary strains and formulations. These products are developed by the Company in cooperation with state-licensed operators who meet the Company’s strict standards, including all natural—not artificial or synthetic—ingredients. The Company licenses its brands and product formulations only to certified manufacturing professionals who follow state cannabis laws and adhere to the Company’s precise scientific formulations and trademarked product recipes.

 

The Company’s proprietary cannabis genetics produce flowers and concentrates under the brand name Nature’s Heritage™, and cannabis-infused products under the brand names Kalm Fusion®, in the form of chewable tablets and drink powder mixes, and the award-winning1 Betty’s Eddies® brand of all natural fruit chews. Both cannabis-infused brands are top selling products in Maryland and Massachusetts2 and the Company intends to introduce additional products under these brands in 2021.

 

The Company also has exclusive sublicensing rights in certain states to distribute the Binske® line of cannabis products crafted from premium artisan ingredients, the Healer™ line of medical full-spectrum cannabis tinctures, and the clinically tested medicinal cannabis strains developed in Israel by global medical cannabis research pioneer Tikun Olam™. The Company intends to continue licensing and distributing its brands as well as other top brands in the Company’s current markets.

 

The Company’s stock is quoted on the OTCQX market under the ticker symbol MRMD.

 

The Company was incorporated in Delaware in January 2011 under the name Worlds Online Inc. Initially, the Company developed and managed online virtual worlds. By early 2014, this line of business effectively ceased operating, and the Company pivoted into the legal cannabis industry.

 

 

1 Awards won by the Company’s Betty’s Eddies® brand include LeafLink 2020 Industry Innovator, Explore Maryland Cannabis 2020 Edible of the Year, and LeafLink 2019 Best Selling Medical Product.

 

2 Source: LeafLink Insights 2020.

 

7
 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

In accordance with GAAP, interim financial statements are not required to contain all of the disclosures normally required in annual financial statements. In addition, the results of operations of interim periods may not necessarily be indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s most recent audited annual financial statements and accompanying notes for the year ended December 31, 2020.

 

Certain reclassifications have been made to prior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries at June 30, 2021:

 

Subsidiary:  Percentage
Owned
 
MariMed Advisors Inc.   100.0%
Mia Development LLC   89.5%
Mari Holdings IL LLC   100.0%
Mari Holdings MD LLC   97.4%
Mari Holdings NV LLC   100.0%
Mari Holdings Metropolis LLC   100.0%
Mari Holdings Mt. Vernon LLC   100.0%
Hartwell Realty Holdings LLC   100.0%
iRollie LLC   100.0%
ARL Healthcare Inc.   100.0%
KPG of Anna LLC   100.0%
KPG of Harrisburg LLC   100.0%
MariMed Hemp Inc.   100.0%
MediTaurus LLC   70.0%

 

Intercompany accounts and transactions have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.

 

Cash Equivalents

 

The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values.

 

The Company’s cash and cash equivalents are maintained with recognized financial institutions located in the United States. In the normal course of business, the Company may carry balances with certain financial institutions that exceed federally insured limits. The Company has not experienced losses on balances in excess of such limits and management believes the Company is not exposed to significant risks in that regard.

 

Accounts Receivable

 

Accounts receivable consist of trade receivables and are carried at their estimated collectible amounts.

 

The Company provides credit to its clients in the form of payment terms. The Company limits its credit risk by performing credit evaluations of its clients and maintaining a reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a client’s outstanding balances with consideration towards such client’s historical collection experience, as well as prevailing economic and market conditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $41.4 million and $40.0 million at June 30, 2021 and December 31, 2020, respectively. Please refer to Note 17 – Bad Debts for further discussion on receivable reserves.

 

8
 

 

Inventory

 

Inventory is carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company allocates a certain percentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard criteria. The Company reviews physical inventory for obsolescence and/or excess and will record a write-down if necessary.

 

Investments

 

Investments are comprised of equity holdings in private companies. These investments are recorded at fair value on the Company’s consolidated balance sheet, with changes to fair value included in income. Investments are evaluated for permanent impairment and are written down if such impairments are deemed to have occurred.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606, Revenue from Contract with Customers, as amended by subsequently issued Accounting Standards Updates. This revenue standard requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. The recognition of revenue is determined by performing the following consecutive steps:

 

  Identify the contract(s) with a customer;
  Identify the performance obligations in the contract(s);
  Determine the transaction price;
  Allocate the transaction price to the performance obligations in the contract(s); and
  Recognize revenue as the performance obligation is satisfied.

 

Additionally, when another party is involved in providing goods or services to the Company’s clients, a determination is made as to who—the Company or the other party—is acting in the capacity as the principal in the sale transaction, and who is merely the agent arranging for goods or services to be provided by the other party.

 

The Company is typically considered the principal if it controls the specified good or service before such good or service is transferred to its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations and risks, (ii) possesses certain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance obligations it does not satisfy.

 

The Company’s main sources of revenue are comprised of the following:

 

  Product Sales – direct sales of cannabis and cannabis-infused products by the Company’s retail dispensaries and wholesale operations in Massachusetts and Illinois, and sales of hemp and hemp-infused products. An increase in product sales is expected from the Company’s planned cannabis-licensee acquisitions in Maryland, Nevada, and Delaware (upon this state’s amendment to permit for-profit ownership of cannabis entities). This revenue is recognized when products are delivered or at retail points-of-sale.
     
  Real Estate – rental income and additional rental fees generated from leasing of the Company’s state-of-the-art, regulatory-compliant cannabis facilities to its cannabis-licensed clients. Rental income is generally a fixed amount per month that escalates over the respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed specified amounts.
     
  Management – fees for providing the Company’s cannabis clients with comprehensive oversight of their cannabis cultivation, production, and dispensary operations. These fees are based on a percentage of such clients’ revenue and are recognized after services have been performed.
     
  Supply Procurement – the Company maintains volume discounts with top national vendors of cultivation and production resources, supplies, and equipment, which the Company acquires and resells to its clients or third parties within the cannabis industry. The Company recognizes this revenue after the delivery and acceptance of goods by the purchaser.
     
  Licensing – royalties from the licensed distribution of the Company’s branded products including Kalm Fusion® and Betty’s Eddies®, and from sublicensing of contracted brands including Healer and Tikun Olam, to regulated dispensaries throughout the United States and Puerto Rico. The recognition of this revenue occurs when the products are delivered.

 

9
 

 

Research and Development Costs

 

Research and development costs are charged to operations as incurred.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred.

 

The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, forty years; tenant improvements, the remaining duration of the related lease; furniture and fixtures, seven to ten years; machinery and equipment, ten years. Land is not depreciated.

 

The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from the undiscounted future cash flows of such asset over the anticipated holding period. An impairment loss is measured by the excess of the asset’s carrying amount over its estimated fair value.

 

Impairment analyses are based on management’s current plans, asset holding periods, and currently available market information. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.

 

For the six months ended June 30, 2021 and 2020, based on the results of management’s impairment analyses, there were no impairment losses.

 

Leases

 

The consolidated financial statements reflect the Company’s adoption of ASC 842, Leases, as amended by subsequent accounting standards updates, utilizing the modified retrospective transition approach.

 

ASC 842 is intended to improve financial reporting of leasing transactions. The most prominent change from previous accounting guidance is the requirement to recognize right-of-use assets and lease liabilities on the consolidated balance sheet representing the rights and obligations created by operating leases that extend more than twelve months in which the Company is the lessee. The Company elected the package of practical expedients permitted under ASC 842. Accordingly, the Company accounted for its existing operating leases that commenced before the effective date as operating leases under the new guidance without reassessing (i) whether the contracts contain a lease, (ii) the classification of the leases (iii) the accounting for indirect costs as defined in ASC 842.

 

The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Non-lease components within lease agreements are accounted for separately. Right-of-use assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

 

Impairment of Long-Lived Assets

 

The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised values.

 

Fair Value of Financial Instruments

 

The Company follows the provisions of ASC 820, Fair Value Measurement, to measure the fair value of its financial instruments, and ASC 825, Financial Instruments, for disclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are:

 

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data.

 

10
 

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable, approximate their fair values due to the short maturity of these instruments.

 

The fair value of option and warrant issuances are determined using the Black-Scholes pricing model and employing several inputs such as the expected life of instrument, the exercise price, the expected risk-free interest rate, the expected dividend yield, the value of the Company’s common stock on issuance date, and the expected volatility of such common stock. The following table summarizes the range of inputs used by the Company during the six months ended June 30, 2021 and 2020:

 

  

Six Months Ended June 30,

 
   2021   2020 
Life of instrument   3.0 to 5.0 years    3.0 years 
Volatility factors   1.230 to 1.266